Recent Patents on Drug Delivery & Formulation
Title:Patent Selections:
Volume: 7 Issue: 1
Author(s):
Affiliation:
Export Options
About this article
Cite this article as:
, Patent Selections:, Recent Patents on Drug Delivery & Formulation 2013; 7 (1) . https://dx.doi.org/10.2174/1872211311307010010
DOI https://dx.doi.org/10.2174/1872211311307010010 |
Print ISSN 1872-2113 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4039 |
9
Related Articles
-
Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG
Current Alzheimer Research Exercise-Induced Overexpression of Angiogenic Factors and Reduction of Ischemia / Reperfusion Injury in Stroke
Current Neurovascular Research Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety A Review of the Psychometric Properties of the CRAFFT Instrument: 1999-2010
Current Drug Abuse Reviews The Role of FKBP5 in Mood Disorders: Action of FKBP5 on Steroid Hormone Receptors Leads to Questions About its Evolutionary Importance
CNS & Neurological Disorders - Drug Targets Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design Ibogaine in the Treatment of Substance Dependence
Current Drug Abuse Reviews Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
Current Drug Research Reviews Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Exercise and Cognitive-Behavioural Treatment in Fibromyalgia Syndrome
Current Pharmaceutical Design The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease
Current Pharmaceutical Design Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Iridoid Compound 10-O-trans-p-Coumaroylcatalpol Extends Longevity and Reduces Alpha Synuclein Aggregation in Caenorhabditis elegans
CNS & Neurological Disorders - Drug Targets Pyridoxal 5-Phosphate Enzymes as Targets for Therapeutic Agents
Current Medicinal Chemistry Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Astrocytes: From the Physiology to the Disease
Current Alzheimer Research CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment
Current Pharmacogenomics and Personalized Medicine Parkinson’s Disease: A Review from Pathophysiology to Treatment
Mini-Reviews in Medicinal Chemistry